A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients. Key to that strategy is our deep expertise in the discovery, design, development, manufacturing, and ultimately commercialization of antibody-drug conjugates and other oncology therapeutics. We are advancing a pipeline that includes three clinical assets and three preclinical assets. Varegacestat, formerly AL102, is an investigational, oral, once-daily gamma secretase inhibitor, or GSI. In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors. We anticipate submitting a new drug application, or NDA, in the second quarter of 2026.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -212M | -212M | -293M | -107M | -38M | -25M |
| EPS | $-2.43 | $-2.43 | $-5.00 | $-5.38 | $-3.09 | $-2.14 |
| Free Cash Flow | -201M | -201M | -118M | -8.4M | -29M | -18M |
| ROIC | -25.9% | -52.1% | -161.7% | -89.1% | -175.1% | -51.1% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.01 | 0.44 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -224M | -224M | -306M | -110M | -37M | -25M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -33.5% | -52.1% | -161.7% | -89.1% | -225.3% | -51.3% |
| Shares Outstanding | 87M | 87M | 59M | 87M | 60M | 12M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 8.8M | 7.5M | 14M | 23M | 23M | 130M | 177M | 177M |
| SG&A | 1.5M | 4.8M | 11M | 14M | 20M | 33M | 44M | 44M |
| EBIT | -10M | -12M | -25M | -37M | -110M | -306M | -224M | -224M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -10M | -18M | -25M | -38M | -107M | -293M | -212M | -212M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -161.6% | -43.0% | -51.1% | -175.1% | -89.1% | -161.7% | -52.1% | -25.9% |
| ROE | N/A | -43.1% | -51.3% | -225.3% | -89.1% | -161.7% | -52.1% | -33.5% |
| ROA | -206.4% | -40.1% | -42.7% | -156.0% | -71.9% | -121.9% | -46.0% | -31.1% |
| Cash Flow | ||||||||
| Op. Cash Flow | -9.6M | -12M | -18M | -29M | -7.6M | -111M | -191M | -191M |
| Free Cash Flow | -9.8M | -13M | -18M | -29M | -8.4M | -118M | -201M | -201M |
| Owner Earnings | -10M | -14M | -22M | -34M | -14M | -128M | -219M | -219M |
| CapEx | 233K | 586K | 79K | 248K | 831K | 7.2M | 9.7M | 9.7M |
| Maint. CapEx | 615K | 755K | 755K | 422K | 457K | 1.6M | 2.5M | 2.5M |
| Growth CapEx | 0 | 0 | 0 | 0 | 374K | 5.6M | 7.2M | 7.2M |
| D&A | 615K | 755K | 755K | 422K | 457K | 1.6M | 2.5M | 2.5M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 14K | 621K | 3.4M | 5.3M | 6.2M | 16M | 26M | 26M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -4.6M | -79M | -98M | N/A | -137M | -213M | -650M | -650M |
| Cash & Equiv. | 2.5M | 40M | 49M | 20M | 99M | 143M | 653M | 653M |
| Long-Term Debt | N/A | 134K | 134K | N/A | N/A | N/A | N/A | 3.9M |
| Debt/Equity | -0.01 | 0.02 | 0.01 | 0.44 | 0.01 | 0.03 | 0.01 | 0.01 |
| Interest Coverage | -107.8 | -322.7 | -2520.4 | -7380.2 | -40.2 | -23.8 | -19.1 | -19.1 |
| Equity | -36M | 41M | 48M | 17M | 120M | 181M | 634M | 634M |
| Total Assets | 5.1M | 45M | 58M | 24M | 149M | 240M | 683M | 683M |
| Total Liabilities | 1.8M | 3.2M | 9.7M | 7.4M | 29M | 59M | 49M | 49M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -37M | -54M | -79M | -116M | -223M | -516M | -728M | -728M |
| Working Capital | 1.5M | 40M | 47M | 15M | 123M | 167M | 616M | 616M |
| Current Assets | 3.1M | 43M | 57M | 23M | 145M | 221M | 661M | 661M |
| Current Liabilities | 1.7M | 3.0M | 9.7M | 7.3M | 22M | 54M | 45M | 45M |
| Per Share Data | ||||||||
| EPS | -9.55 | -5.26 | -2.14 | -3.09 | -5.38 | -5.00 | -2.43 | -2.43 |
| Owner EPS | -0.96 | -1.11 | -1.94 | -0.58 | -0.16 | -2.19 | -2.51 | -2.51 |
| Book Value | -3.34 | 3.41 | 4.17 | 0.28 | 1.38 | 3.09 | 7.26 | 7.26 |
| Cash Flow/Share | -0.90 | -1.00 | -1.58 | -0.48 | -0.09 | -1.89 | -2.18 | -2.40 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 10.7M | 12.1M | 11.5M | 59.7M | 87.0M | 58.6M | 87.4M | 87.4M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -9.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 3.0 | 3.6 | 9.1 | 7.8 | 3.4 | 3.0 | 3.2 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -10.2% | -10.6% | -19.1% | -0.9% | -19.1% | -10.6% | -10.0% |
| Market Cap | N/A | 124M | 173M | 152M | 933M | 618M | 1.9B | 2.0B |
| Avg. Price | N/A | 11.77 | 20.41 | 5.12 | 6.45 | 15.52 | 11.25 | 22.90 |
| Year-End Price | N/A | 10.25 | 15.02 | 2.54 | 10.73 | 10.54 | 21.71 | 22.90 |
Immunome Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Immunome Inc. (IMNM) has a 5-year average return on invested capital (ROIC) of -105.8%. This is below average and may indicate limited pricing power.
Immunome Inc. (IMNM) has a market capitalization of $2.0B. It is classified as a mid-cap stock.
Immunome Inc. (IMNM) does not currently pay a regular dividend.
Immunome Inc. (IMNM) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Immunome Inc. (IMNM) generated $-201 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Immunome Inc. (IMNM) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
Immunome Inc. (IMNM) reported earnings per share (EPS) of $-2.43 in its most recent fiscal year.
Immunome Inc. (IMNM) has a return on equity (ROE) of -52.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Immunome Inc. (IMNM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Immunome Inc. (IMNM) has a book value per share of $7.26, based on its most recent annual SEC filing.